T he most common and potentially remediable cause of treatment failure in patients with schizophrenia is lack of adherence to prescribed oral medications. 1,2 By ensuring sustained levels of drug in the blood, long-acting injectable delivery may improve adherence and symptom control and reduce the rate of relapse and hospitalization. [2] [3] [4] [5] In the United States, the first second-generation antipsychotic agent to be made available in a longacting injectable delivery system was risperidone (Risperdal Consta, Ortho-McNeil Janssen). Longacting injectable risperidone may cause fewer extrapyramidal symptoms than the long-acting injectable first-generation antipsychotic agents. 6 A randomized trial showed the efficacy of long-acting injectable risperidone over placebo in patients with schizophrenia, 7 and before-andafter studies have shown tolerability in switching from oral to long-acting injectable risperidone, with improved symptoms and reduced hospital use. [8] [9] [10] [11] These studies involved clinically stable patients and lacked randomized control groups. Three randomized trials that also involved patients with stable disease showed no advantage of long-acting injectable risperidone therapy over oral treatment. [12] [13] [14] In this trial involving patients with unstable disease, we hypothesized that long-acting injectable risperidone would be superior in reducing the risk of hospitalization for up to 2 years as compared with a psychiatrist's choice of an oral antipsychotic.
Me thods

Participants
Patients were eligible to participate in the study if they were 18 years of age or older, had a diagnosis of schizophrenia or schizoaffective disorder as assessed with the use of the Structured Clinical Interview based on the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders, 15 and were at risk for psychiatric hospitalization as evidenced by current psychiatric hospitalization, hospitalization in the previous 2 years, or increased use of mental health services to prevent relapse as adjudicated by the study chairpersons (the first two authors). The original entry criteria required hospitalization in the previous year but were extended to enhance recruitment (see the study protocol, available with the full text of this article at NEJM.org).
Randomization began in September 2006, and data collection continued for 3 years, with 209 of 369 patients (56.6%) randomly assigned in the first year, 140 patients (37.9%) assigned in the second year, and 20 patients (5.4%) assigned during the first 3 months of the third year. Follow-up continued for up to 2 years.
Exclusion criteria were the following: detoxification in the previous month; reported past intolerance to risperidone or intramuscular injections; current treatment with long-acting injectable antipsychotics, oral clozapine, warfarin, or a combination of these agents; serious medical conditions; unstable living arrangements; and a history of assault or suicidal behavior requiring urgent intervention.
The patients' decisional capacity was assessed with the use of the MacArthur Competence Assessment Tool. 16 Guardian consent was allowed. Subjects received payment for their travel expenses and time: $25 for monthly and injectiononly visits and $45 for extended quarterly assessment visits. The injectable-risperidone group thus had more planned paid visits than the oral-antipsychotic group. After written informed consent had been obtained from the patient or guardian, testing for allergic reactions was performed with an oral test dose of 1 mg of risperidone. Longacting injectable risperidone was provided free of charge by Ortho-McNeil Janssen Scientific Affairs, which had no role in the study.
The study and consent forms were approved by the institutional review boards of the 19 collaborating centers. The analyses were conducted at the Veterans Affairs (VA) Cooperative Studies Program Coordinating Center, Boston, and the VA Health Economics Resource Center, Menlo Park, California. All authors designed the trial, interpreted the findings, agreed to publication of the manuscript, and reviewed and approved the manuscript. The first author wrote the first draft of the manuscript. All authors vouch for the completeness and accuracy of the data, the data analyses, and the fidelity of this report to the study protocol.
Randomization
Randomization was conducted centrally and stratified according to site because of potential practice differences. Randomization was conducted with the use of randomly permuted blocks of variable size to ensure an approximate balance over time.
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Treatment Groups
Patients randomly assigned to long-acting injectable risperidone were seen clinically by a study nurse every 2 weeks for the first month and then monthly. All patients were seen monthly by their psychiatrist and by the nurse. On the basis of consensus guidelines, 17 long-acting injectable risperidone was administered intramuscularly at an initial dose of 25 mg every 2 weeks. Dosage increments of 12.5 mg were permitted every 4 weeks at the discretion of the treating psychiatrist, up to the maximum approved dose of 50 mg.
Steady-state drug levels are reached 6 to 8 weeks after initiation of treatment with long-acting injectable risperidone, 17 and efforts to reduce the use of oral antipsychotics subsequently were encouraged in the injectable-risperidone group. Previous oral antipsychotics were to be continued for at least 3 weeks. Treatment interruptions among patients randomly assigned to long-acting injectable risperidone were addressed by restarting the intramuscular medication and providing oral medication for 3 weeks if the interruption occurred before the steady state was reached, or if the interruption was longer than 6 weeks.
Concomitant psychotropic medications (i.e., antianxiety agents, antidepressants, and oral antipsychotics and mood stabilizers) and anticholinergic medications were allowed.
Control-group participants continued to receive oral antipsychotic therapy as prescribed by their treating physician. Treating psychiatrists were given a summary of optimal dosage ranges for oral antipsychotic and anticholinergic agents, based on published recommendations. 18 
Concomitant Psychosocial Treatment
To ensure that no patient was randomly assigned to less than standard best practice -an ethical imperative -a short checklist of potentially useful ancillary psychosocial services available at the participating centers was provided to all participants during follow-up visits. 19 
Measures
Blinded videoconference assessments were completed every 3 months on measures of symptoms, quality of life, and functioning.
At a monthly unblinded meeting with the study nurse, the Clinical Global Impressions (CGI) scale 20 was used to assess the patient's global mental health status and the change from baseline (on a scale of 1 to 7, with higher scores indicating poorer functioning or less improvement). Satisfaction with medication was measured with the use of the Drug Attitude Inventory (on a scale of 1 to 20, with higher scores indicating greater satisfaction). 21 Retention on the assigned drug was measured according to the number of days until discontinuation of the assigned treatment or, among participants assigned to the oral medication, days to crossover to any new oral or long-acting injectable treatment. The use of long-acting injectable risperidone was documented according to study prescribing records, and the use of oral medication was documented according to patient interviews. Efforts were made to ensure that patients continued to receive the medications selected by their doctor if they discontinued the study drug.
Symptoms of schizophrenia were measured according to the total score on the Positive and Negative Syndrome Scale (PANSS, which ranges from 30 to 210, with higher scores indicating more symptoms), and its positive, negative, and general subscales. 22 PANSS ratings were obtained from standardized videoconferences conducted by trained raters from MedAvante who were unaware of the patients' study-drug assignments. Psychiatric assessments by video conference are reliable in patients with schizophrenia and are well received. 23 Subjective psychological distress was measured with the use of the depression and anxiety subscales of the Brief Symptom Index (on a scale of 0 to 4, with higher scores indicating greater distress). 24 
Quality of Life and Social Functioning
Quality of life was measured with the use of the Heinrichs-Carpenter Quality of Life Scale (ranging from 0 to 120, with higher scores indicating better quality of life) 25 and the Personal and Social Performance scale (ranging from 1 to 100, with higher scores reflecting better functioning), 26 the latter providing a global assessment of social functioning. Both were administered by videoconference assessors who were unaware of the study-drug assignments.
Health-related quality of life was assessed with the use of the Quality of Well-Being scale (ranging from 0 to 1, with higher scores indicating greater well-being), 27 which has been validated for use in schizophrenia. 28 
Substance Use
At screening, physicians and patients were asked whether substance abuse was a problem. Alcohol and drug use in the previous 30 days was assessed with the use of the alcohol and drug composite indexes from the Addiction Severity Index (on a scale of 0 to 1, with higher scores indicating more severe problems). 29 
Side Effects
Neurologic side effects were measured with the use of three scales. [30] [31] [32] Sexual dysfunction was measured with items from the Novel Antipsychotic Medication Experience Scale (ranging from 0 to 4, with higher scores indicating worse side effects) (Ames D: personal communication).
Hospitalization and Use of Other Medical Services
Administrative data on service use, including hospitalizations, were available for all VA health services. Psychiatric inpatient admissions were identified through the VA's Patient Treatment File. Non-VA admissions were identified according to discharge summaries validated as psychiatric by a physician who was unaware of the patients' study-drug assignments.
The primary outcome measure was the time from randomization to psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization. The key secondary outcome measure was the change in the PANSS total score at 12 months. Secondary analyses compared outcomes at all time points up to 18 months, rather than the difference between follow-up scores and baseline scores at one specific time point.
Statistical Analysis
The planned sample size of 450 patients (the original sample size of 600 was resized because of recruitment difficulties) provided 90% power for analyses of our primary outcome and secondary outcome, each with a two-sided test and a type I error of 2.5% (i.e., 1.25% in each tail). First, a time-to-event analysis, with the use of the logrank test, compared the hazard ratios associated with the time to the first psychiatric hospitalization. With a null hypothesis that the hazard ratio would equal 1, the alternative hypothesis was that for long-acting injectable risperidone versus oral agents, the hazard ratio was greater than or equal to 1.65 or less than or equal to 0.60. This hypothesis was derived from an assumption based on three studies in which baseline rates of relapse were approximately 41% in the oral-antipsychotic group and approximately 25% in the intramuscular-medication group (i.e., a rate ratio of 1.64 [41 ÷ 25] corresponding to a difference of 16 percentage points [41% -25%] in the annual rate of a first psychiatric hospitalization). 2, 33, 34 The follow-up period for this outcome was up to 2 years, terminating with hospitalization or discontinuation of the assigned study medication.
Confirmatory Cox proportional-hazards analyses controlled for potential confounding factors. These factors included prior use of risperidone, history of substance abuse, and hospitalization at the time of enrollment.
A repeated-measures mixed-effects model was used to compare the mean change from baseline to 12 months in the PANSS score for injectable and oral treatments. With a null hypothesis of no difference, the alternative hypothesis was that the difference was greater than or equal to 5 units or less than or equal to -5 units. The model had fixed effects for treatment group and time (a categorical variable); the interaction of treatment with time, site, and individual patients were treated as random effects. A first-order autocorrelation structure was used. The baseline PANSS score was added to the model to assess its effect on changes from baseline. Confirmatory mixed models were run with the PANSS score.
Further descriptive analysis of outcome and side-effect measures used mixed models of all outcome data up to 18 months because of extensive sample attrition after that time. Because of the skewed distribution of service use, the significance of differences was tested with the Wilcoxon rank-sum test.
R e sult s
Study Participants
Altogether, 1045 patients were screened at 19 VA medical centers between 2006 and 2009, yielding a final analytic sample of 369 patients (Fig. 1) . Five sites discontinued the study because of insufficient recruitment. Participants were hospitalized at the time of randomization (40%), had been hospitalized within the previous 2 years (55%), or had recent increased service use indicating a risk of hospitalization (5%). At screening, problems with medication adherence were reported for 64% of the patients; 43% of the patients reported problems by themselves and in 60% of the cases, problems were reported by physicians. Active problems with alcohol or drug use were reported for 37% of the patients; 25% were reported by the participants and 36% were reported by their physicians. There were no significant differences between groups at baseline in this sample of older male veterans ( Table 1 in the Supplementary Appendix, available at NEJM.org).
Treatment and Follow-Up Assessments
For patients assigned to and receiving long-acting injectable risperidone, at 6 weeks, 86% of injection doses were 25 mg, 11% were 37.5 mg, and 3% were 50 mg, with an average of 1.8 injections per month. During the remainder of the trial, 17% of doses were 25 mg, 31% were 37.5 mg, and 50% were 50 mg, with an average of 1.5 injections per month (the percentages do not sum to 100 because of rounding). During the first 6 weeks, 40% of patients receiving long-acting injectable risperidone received concomitant oral antipsychotics. During the remainder of the trial, 32% of injections were accompanied by prescriptions for oral antipsychotics during the same month.
The follow-up interview rates in the intentionto-treat analysis were as follows: 60% (223 patients) at 1 year, 46% (170) at 18 months, and 29% (107) at 24 months, with no significant differences between groups at these time points (P = 0.42 to 0.99). The mean (±SD) duration of participation was 474±235 days for long-acting injectable risperidone versus 502±226 days for oral antipsychotics (P = 0.22). 
Outcomes
Long-acting injectable treatment was not superior to oral treatment in the duration of adherence to the randomized treatment (P = 0.19) (Fig. 1 in the Supplementary Appendix). Among participants receiving oral treatment, however, 21 of 182 (12%) switched to long-acting injectable risperidone an average of 153±203 days after randomization. There were no significant differences with respect to the initiation of concomitant psychotropic medications (Fig. 2 in the Supplementary  Appendix) .
A total of 237 of 369 patients (64%) continued to receive the study drug throughout their participation in the study. Reasons for medication discontinuation were not significantly different between groups ( Table 2 in the Supplementary Appendix).
With a mean follow-up of 11.3 and 10.8 months, respectively, 81 of 182 (45%) patients receiving oral medication and 72 of 187 (39%) receiving long-acting injectable risperidone were hospitalized. Long-acting injectable risperidone was not superior to oral treatment with respect to the time to hospitalization (P = 0.39 by the log-rank test; hazard ratio, 0.87, 95% confidence interval [CI], 0.63 to 1.20) (Fig. 2 ). An analysis that excluded the 21 subjects who switched from an oral antipsychotic to long-acting injectable risperidone provided similar results (hazard ratio, 1.00; 95% CI, 0.71 to 1.40), as did an analysis that was adjusted for covariates (hazard ratio, 0.82; 95% CI, 0.59 to 1.13).
The mixed-model analysis of the change from baseline to 12 months in the PANSS total score did not show superiority of long-acting injectable risperidone (P = 0.72).
Further outcome comparisons across all time points up to 18 months showed no significant between-group differences in the PANSS total score or subscales ( Table 1 , and Fig. 3 in the Supplementary Appendix). No significant superiority of long-acting injectable risperidone was observed on the blindly rated Heinrichs-Carpenter Quality of Life Scale or its subscales, the Personal and Social Performance scale or the selfreported Quality of Well-Being scale, the current CGI functioning measure, or the Addiction Severity Index composite drug scores ( Table 1) . The composite alcohol index of the Addiction Severity Index was higher in the oral-antipsychotic group (P = 0.04) and the Drug Attitude Inventory favored long-acting injectable risperidone (P = 0.02). Although there was no superiority of long-acting injectable risperidone on the unblinded assessment of illness severity at each time point, the unblinded CGI improvement score, representing the rater-perceived change from baseline, favored long-acting injectable risperidone (P<0.001).
Analysis of adverse events ( Table 3 in the Supplementary Appendix) showed that patients who received long-acting injectable risperidone had more "general disorders and administration site conditions" (injection-related pain or induration) (P = 0.04) and "nervous system disorders" (headache and extrapyramidal signs and symptoms) (P<0.001). There were four deaths. In the injectable-risperidone group, one patient died in his sleep from an unknown cause and another committed suicide. In the oral-antipsychotic group, one patient died from chronic obstructive pulmonary disease, and another from accidental drowning.
Use of Services
A larger proportion of patients receiving longacting injectable risperidone were hospitalized at the time of randomization and they were hospitalized for more days during the period before randomization (Table 2 ). After randomization, there were no significant differences between groups with respect to VA service use (Table 2) or non-VA service use ( Table 4 in In this analysis, data on patients who withdrew from the study were censored at the time of withdrawal from the study.
The 
Discussion
This randomized, controlled trial showed that in high-risk patients with schizophrenia or schizoaffective disorder, long-acting injectable risperidone was not superior to oral antipsychotics with respect to the primary outcome of time to hospitalization, or multiple standard measures of symptoms, quality of life, side effects, or service use. Greater numbers of adverse events were reported by the injectable-risperidone group. These events primarily included injection-site phenomena, headache, and extrapyramidal signs and symptoms, suggesting that patients receiving oral medication may flexibly adjust their medication use to avoid such adverse effects. The duration of treatment with long-acting injectable risperidone was not significantly longer than the duration of treatment with oral antipsychotics. The findings were not modified by the addition of covariates or the exclusion of crossover observations (for participants who switched from oral to long-acting injectable treatment). Differences in the alcohol composite index of the Ad- diction Severity Index and the Drug Attitude Inventory were not significant after adjustment for multiple comparisons. Although the current CGI scores assigned by raters who were aware of the patients' study-drug assignments did not differ between groups, the CGI improvement scores assigned by these raters indicated significantly greater improvement in the group of patients who received long-acting injectable risperidone, suggesting an unblinded rater bias favoring longacting injectable risperidone. Taken together, these findings are consistent with three efficacy trials that also showed no superiority of long-acting injectable risperidone over oral regimens in patients with stable schizophrenia. [12] [13] [14] Two studies have suggested that unintended intramuscular injections into fat tissue may decrease pharmacologic effectiveness, but this was not assessed in our study. 35, 36 Our study had several limitations. First, 12% of control patients received long-acting injectable risperidone treatment an average of 5 months into the trial. This may have biased the results in favor of oral treatment in the intention-totreat analysis. Replication of the analyses of hospitalization risk and blinded outcomes excluding observations after these crossovers or discontinuation of long-acting injectable risperidone yielded no significant findings favoring long-acting injectable treatment.
Second, the dose of long-acting injectable risperidone may have been inadequate in some patients, and some injections were missed, but this reflects the real-world practice that was the focus of this effectiveness study.
Third, decisions regarding hospitalization were unblinded, and the direction of any bias is unknown. If physicians thought there was less need to hospitalize patients, knowing that they were receiving ample medication, the bias could favor long-acting injectable risperidone. On the other hand, if admitting physicians knew that patients receiving long-acting risperidone were symptomatic in spite of being adequately medicated, the bias could favor oral treatment.
Fourth, this sample involved older, primarily male veterans, and results may not be generalizable to other populations.
Finally, although our revised target sample was 450 subjects, we enrolled only 382 subjects, and data were available for only 369 because of early dropouts. Dropout patterns and sample sizes were similar to those of previous schizophrenia trials. 36, 37 Our study did not show the superiority of long-acting injectable risperidone, but the confidence intervals for the time to hospitalization were fairly wide (hazard ratio, 0.87; 95% CI, 0.63 to 1.20) , and the study was not large enough to exclude modest differences between the groups.
